Researchers identify new therapeutic target for metastatic prostate cancer

(Rockefeller University Press) Researchers in New York have found that treating human prostate cancer cells with a drug that targets a protein called PHLPP2 may prevent the cancer cells from spreading to other organs in the body. The study, which will be published May 15 in the Journal of Cell Biology, reveals that inhibiting PHLPP2 lowered the levels of MYC, an oncogenic protein that causes many different types of cancer that cannot be targeted by conventional drug therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

The prostate cancer community mourns the loss of Gerald Chodak, MD, an influential and iconic figure in urology.Medscape Urology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Urology News Source Type: news
Publication date: Available online 15 October 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Therina du Toit, Amanda C. SwartAbstractIn clinical approaches to benign prostatic hyperplasia (BPH) and prostate cancer (PCa), steroidogenesis or the disruption thereof is the main thrust in treatments restricting active androgen production. Extensive studies have been undertaken focusing on testosterone and dihydrotestosterone (DHT). However, the adrenal C11-oxy C19 steroid, 11β-hydroxyandrostenedione (11OHA4), also contributes to the active androgen pool in the prostate microenvironment, and...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
The diagnosis of prostate cancer has changed. Improved magnetic resonance imaging (MRI) technology with diffusion-weighted imaging has led to the use of multiparametric MRI (mpMRI) before biopsy in patients suspected of having prostate cancer. This has the advantage that patients with a negative mpMRI may not need biopsy, therefore avoiding the risk of complications. Those in whom mpMRI is positive can have targeted biopsies with a higher probability of diagnosing clinically significant cancer. Prostate Cancer UK (PCUK) and the British Society of Urogenital Radiology submitted a Freedom of Information (FOI) request in 2016...
Source: Clinical Radiology - Category: Radiology Authors: Tags: Review Source Type: research
The UK National Institute for Health and Care Excellence (NICE) 2019 “Prostate cancer: diagnosis and management” guidelines have recommended that all patients suspected of prostate cancer undergo multiparametric magnetic resonance imaging (mpMRI) prior to biopsy. The Likert scoring system is advocated for mpMRI reporting based on multicentre studies that have dem onstrated its effectiveness within the National Health Service (NHS). In recent years, there has been considerable drive towards standardised prostate reporting, which led to the development of “Prostate Imaging-Reporting And Data System” (PI-RADS).
Source: Clinical Radiology - Category: Radiology Authors: Tags: Pictorial Review Source Type: research
Publication date: Available online 15 October 2019Source: Social Science &MedicineAuthor(s): A. Angelis, M. Linch, G. Montibeller, T. Molina Lopez, A. Zawada, K. Orzel, F. Arickx, J. Espin, P. KanavosAbstractMultiple Criteria Decision Analysis (MCDA) has emerged as a likely methodology for Health Technology Assessment (HTA). However limited empirical evidence is available on its use by decision-makers and only as part of single-setting exercises, without cross-county studies available. This pilot study applies the Advance Value Framework (AVF), an MCDA methodology for HTA based on multi-attribute value theory, through ...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
Authors: Huh JS, Kim YJ, Kim SD, Park KK Abstract PURPOSE: To analyze the clinical parameters correlated with early recovery of urinary continence after radical prostatectomy, with a focus on urethral mobility during pelvic contraction at catheter removal. METHODS: We prospectively analyzed 67 patients who underwent prostatectomy for prostate cancer at Jeju National University Hospital from January 2015 to June 2018. At the time of catheter removal, a cystography was performed in 67 men (median age, 65 years; range, 55-76 years) who had undergone robot-assisted laparoscopic prostatectomy. The vertical length of...
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
Conclusions: Despite the lack of long-term follow-up and heterogeneity of the available evidence, prostate SBRT affords appropriate biochemical control with few high-grade toxicities. These data have implications for ongoing worldwide utilization of prostate SBRT as well as ongoing prospective investigations. PMID: 31608141 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
There is no general consensus on the optimal treatment for prostate cancer (PC) patients with intrapelvic nodal oligorecurrences after radical prostatectomy. Besides androgen deprivation therapy (ADT) as stand...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Publication date: Available online 14 October 2019Source: Trends in GeneticsAuthor(s): Junjie T. Hua, Sujun Chen, Housheng H. HeThe transcriptome of prostate cancer is highly heterogeneous, with noncoding transcripts being essential players. Long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) are two unique classes of noncoding RNA drawing increasing attention. Biologically, they have intriguing properties with important regulatory functions. Clinically, they present as promising biomarkers and therapeutic targets. Recent advancements in technologies have opened up new directions for noncoding RNA research, which in...
Source: Trends in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study we review the principles that have guided the engineering of CAR-T cells and the specific prostatic antigens identified as possible targets for immunological and non-immunological therapies. We also provide a state-of-the-art overview of CAR-T cell therapy in PCa, defining the key obstacles to its development and underlining the mechanisms used to overcome these barriers. At present, although there are still many unanswered questions regarding CAR-T cell therapy, there is no doubt that it has the potential to become an important treatment option for urological malignancies.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cytology | Prostate Cancer | Study